Skip to main content
OpenTrials
Completed

NCT Number: NCT00296894

Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Patients will be randomized into two groups (1/1) during one year:

* 40 mg adalimumab subcutaneously (sc) every other week * placebo

The effect on x-rays and clinical parameters will be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Erosive Osteo-Arthritis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University Hospital Ghent

Ghent, 9000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clear erosive image on x-ray of at least one interphalangeal finger joint

Treatment and study plan

Adalimumab (40 mg sc every other week)

Drug

Adalimumab (40 mg sc every other week)

Placebo

Drug

Placebo

Primary outcomes

  1. Evaluation of x-rays

  2. Evaluation of clinical parameters (pain, daily functioning, etc.)

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Registry information

Official study title

TNF-Blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints: Randomized, Double Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of Adalimumab 40 mg SC Every Other Week in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Feb 27, 2006
Registry last updated
Feb 9, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.